{"id":64890,"date":"2026-05-09T21:39:11","date_gmt":"2026-05-09T13:39:11","guid":{"rendered":"https:\/\/flcube.com\/?p=64890"},"modified":"2026-05-09T21:39:12","modified_gmt":"2026-05-09T13:39:12","slug":"wenda-pharmaceutical-secures-nmpa-breakthrough-therapy-designation-for-nhwd-870-in-rare-nut-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64890","title":{"rendered":"Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma"},"content":{"rendered":"\n

Zhejiang Wenda Pharmaceutical Technology Co., Ltd.<\/strong> announced it has received Breakthrough Therapy Designation (BTD)<\/strong> from China’s National Medical Products Administration (NMPA)<\/strong> for NHWD-870 HCI<\/strong>, its oral BET inhibitor<\/strong>, for the treatment of advanced thoracic midline (NUT) carcinoma<\/strong> in patients who have failed prior chemotherapy. This marks a critical advancement for a devastating rare cancer with no currently approved targeted therapies worldwide.<\/p>\n\n\n\n

Disease Burden & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Disease<\/strong><\/td>NUT carcinoma (NUT midline carcinoma)<\/td><\/tr>
Genetic Marker<\/strong><\/td>NUTM1 gene rearrangement<\/td><\/tr>
Median Overall Survival<\/strong><\/td>6.5 months (historical standard)<\/td><\/tr>
Typical Onset Age<\/strong><\/td>23.6 years (median)<\/td><\/tr>
Common Locations<\/strong><\/td>Lungs and head-and-neck regions<\/td><\/tr>
Diagnostic Challenges<\/strong><\/td>High rates of misdiagnosis and underdiagnosis due to non-specific symptoms<\/td><\/tr>
Current Treatment Landscape<\/strong><\/td>No effective targeted therapies available globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

NUT carcinoma represents one of oncology’s most aggressive and challenging malignancies, typically affecting young adults and progressing rapidly to advanced stages before diagnosis.<\/p>\n\n\n\n

Clinical Data Supporting BTD<\/h2>\n\n\n\n

The Breakthrough Therapy Designation is based on compelling efficacy data from Wenda’s Phase II clinical study<\/strong>:<\/p>\n\n\n\n

Endpoint<\/th>Result<\/th><\/tr><\/thead>
Study Population<\/strong><\/td>40 evaluable patients with advanced NUT carcinoma (as of December 27, 2025)<\/td><\/tr>
Objective Response Rate (ORR)<\/strong><\/td>45.00% in 20 patients with advanced thoracic NUT carcinoma<\/td><\/tr>
Median Overall Survival (mOS)<\/strong><\/td>9.33 months for thoracic NUT carcinoma patients<\/td><\/tr>
Overall Study mOS<\/strong><\/td>9.33 months (entire population)<\/td><\/tr>
Survival Benefit<\/strong><\/td>Significant extension compared to conventional chemotherapy (6.5 months historical)<\/td><\/tr>
Safety Profile<\/strong><\/td>Generally well-tolerated with high potential for clinical application<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The 45% ORR<\/strong> and 9.33-month median survival<\/strong> represent substantial improvements over the natural history of this aggressive disease.<\/p>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n